Brainstorm Cell Therapeutics Inc. (BCLI )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol BCLI
- Company Brainstorm Cell Therapeutics Inc.
- Price $0.66
- Changes Percentage 8.18
- Change 0.05
- Day Low $0.64
- Day High $0.72
- Year High $1.92
- Year Low $0.46
- Market Cap $7,282,952
- Price Avg 50 EMA (D) $0.58
- Price Avg 200 EMA (D) $0.78
- Exchange NASDAQ
- Volume 11,605
- Average Volume 23,910
- Open $0.64
- Previous Close $0.61
- EPS -1.42
- PE -0.46
- Earnings Announcement 2026-03-31 21:00:00
- Shares Outstanding $11,034,775
Company brief: BRAINSTORM CELL THERAPEUTICS INC. (BCLI )
- Healthcare
- Biotechnology
- Mr. Chaim Lebovits
- https://www.brainstorm-cell.com
- US
- N/A
- 10-07-2003
- US10501E2019
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
BCLI Corporation News
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
prnewswire.com -- NEW YORK, Feb. 20, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has entere...